Pfizer's Acquired Obesity Drug PF-3944 Shows 12.3% Weight Loss, Targets 2028 Approval
PFE is trading near its 52-week low of $23.11 (11% above the low).
Summary
Pfizer's obesity drug candidate, PF-3944, acquired through the Metsera buyout, demonstrated up to 12.3% mean weight loss at 28 weeks with monthly injections. This follows the previously announced acquisition of Metsera's obesity assets on April 1st. The strong efficacy data for PF-3944 positions it as a competitive asset in the rapidly growing obesity market, adding significant potential to Pfizer's pipeline. The company is targeting first approval for PF-3944 by 2028.
At the time of this announcement, PFE was trading at $25.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $146.5B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.